-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
-
Summary
-
Protalix BioTherapeutics, Inc. quarterly/annual Current Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q3 2024.
- Protalix BioTherapeutics, Inc. Current Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $164K, a 72.6% increase year-over-year.
- Protalix BioTherapeutics, Inc. annual Current Income Tax Expense (Benefit) for 2023 was $3.35M, a 531% increase from 2022.
Current Income Tax Expense (Benefit), Trailing 12 Months (USD)
Current Income Tax Expense (Benefit), Quarterly (USD)
Current Income Tax Expense (Benefit), YoY Quarterly Growth (%)